| Abstrakt: |
Objectives: Royal jelly is a substance that appears to be effective on the immune system and it appears to be effective on both prevention and growth of cancer cells. In this study, we aimed to investigate the effect of royal jelly on the growth of WEHI-164 fibrosarcoma cells in syngenic Balb/c mice. Materials and Methods: In an experimental study, 28 male Balb/c mice were designated into four identical groups. The mice were subcutaneously injected with 5x105 WEHI-164 tumor cells on day zero in the chest area. Animals in groups 1 to 4 were orally given 100, 200, 300 mg/kg of royal jelly or vehicle, respectively. In every individual mouse, the tumor size was measured every 2 days from day 5 (days 5, 7, 9, 11, 13, 15, and 17). Data were statistically analyzed using Kruskal-Wallis and Mann Whitney-U tests. Results: Our results showed that the mean size of tumors in the case group was significantly smaller than the control group in days 11, 13, 15 and 17 (p<0.05). No metastasis was seen in test and control groups. Conclusion: Our study with emphasize on antitumor effects of royal jelly, reveals that royal jelly has an important role in control and regression of fibrosarcoma cells. Since royal jelly showed a delayed effect in control of fibrosarcoma, we suggest that royal jelly be used for at least 10 days before tumor inoculation. [ABSTRACT FROM AUTHOR] |
